Cantor Fitzgerald raised the firm’s price target on Intra-Cellular to $130 from $120 and keeps an Overweight rating on the shares. Intra-Cellular reported strong Q2 results, including a CAPLYTA beat, the analyst tells investors in a research note. The firm views Intra-Cellular as an undervalued Neuro-Innovator with an increasingly well-established commercial franchise and an emerging pipeline with non-zero potential.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
- Intra-Cellular Therapies Welcomes New CFO Sanjeev Narula
- Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
- Intra-Cellular appoints Sanjeev Narula as CFO
- Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance